80 299

Cited 49 times in

Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy

Kwon, SR; Lim, MJ; Suh, CH; Park, SG; Hong, YS; Yoon, BY; Kim, HA; Choi, HJ; Park, W
Rheumatology international, 32(8):2523-2527, 2012
Journal Title
Rheumatology international
(1) To compare the serum levels of Dickkopf-1 (DKK-1) and bone biomarkers in patients with ankylosing spondylitis (AS) and healthy controls. (2) To examine the effects of anti-tumor necrosis factor-α (TNF-α) therapy for 3 months on bone biomarkers in patients with AS. We measured the levels of DKK-1, osteocalcin, osteoprotegerin, and C-terminal telopeptide of type I collagen (CTX-1) in patients with AS and in healthy controls at baseline and 3 months after initiating anti-TNF-α therapy in AS patients. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores were also measured before and after anti-TNF-α therapy in AS patients. Serum levels of DKK-1 were significantly lower in the AS patients than in the controls (P < 0.0001). Osteocalcin and osteoprotegerin levels were significantly higher in the AS patients than in the controls (P < 0.0001). Serum levels of DKK-1 were not changed after the 3-month anti-TNF-α therapy. Osteocalcin level increased (P < 0.0001), osteoprotegerin level and BASDAI scores decreased (P = 0.025 and P < 0.0001, respectively) significantly after the 3-months anti-TNF-α therapy. Serum DKK-1 level was lower in patients with AS than in healthy controls and did not change after 3 months of anti-TNF-α therapy in the AS patients despite the marked improvement in BASDAI scores. These findings suggest the low serum DKK-1 level is related to the pathogenesis of new bone formation in AS, which is resistant to TNF-α blocking therapy.
MeSH terms
AdultAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, Humanized/therapeutic useBiological Markers/bloodCase-Control StudiesCollagen Type I/bloodDown-RegulationFemaleHumansImmunoglobulin G/therapeutic useImmunologic Factors/*therapeutic useIntercellular Signaling Peptides and Proteins/*bloodMaleMiddle AgedOsteocalcin/bloodOsteogenesis/drug effectsOsteoprotegerin/bloodPeptides/bloodReceptors, Tumor Necrosis Factor/therapeutic useRepublic of KoreaSeverity of Illness IndexSpondylitis, Ankylosing/*blood/diagnosis/*drug therapy/immunologyTime FactorsTreatment OutcomeTumor Necrosis Factor-alpha/*antagonists & inhibitors
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Rheumatology
AJOU Authors
서, 창희김, 현아
Files in This Item:
fulltext not available.txtDownload
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.